CD8A and neoplasm: The study demonstrated that by identifying immunogenic neoantigens and developing a delivery system through tumor-specific oncolytic VV, neoantigen vaccines could significantly induce neoantigen-specific CD8+ T cell responses with notable anti-tumor effects 98.